SecBot SecBot
8-K ·Filed Nov 3, 2026

ARVN

ARVINAS, INC.
BEARISH
Impact 5/10
Horizonmonths Processed13d 18h ago SEC0001628280-26-069101
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The revenue cliff from the Pfizer deal transition is now fully reflected. The stock's valuation will depend entirely on clinical catalysts from ARV-393 (ASH data in December 2026), ARV-027 (1H 2027 data), and ARV-6723 (2H 2027 data). Cash runway into 2H 2028 provides a long no-dilution window, but the company is a pre-commercial biotech with no near-term revenue growth driver.

DirectionBearish
Confidencehigh
Horizonmonths

Drugs in focus

ARVN drug pipeline →

ARV-393

● Neutral Named in this 8-K
Impact
Phase
Phase 1
Time to market
At least several years away. The drug is in Phase 1 dose escalation (estimated primary completion March 2028), requiring Phase 2/3 trials and regulatory review before any potential approval.
Next catalyst
None dated

What to watchThe next hard catalyst is the initial Phase 1 monotherapy dose escalation data for ARV-393, submitted for presentation at the ASH Annual Meeting (Dec 12-15, 2026). Positive safety and early efficacy signals could re-rate the stock from near its 52-week low; any safety or tolerability concerns would be a setback for the BCL6 degrader program. A second data readout is expected in mid-2027.

Price Chart

Loading chart...

Executive Summary

Arvinas reported Q3 2026 revenue of $0.5M, down 98.8% from $41.9M a year ago, as Pfizer collaboration revenue ended after the Rigel out-license. The company's cash position fell to $558.9M from $685.4M at year-end 2025, with cash used in operations of $123.0M in the first nine months. Pipeline progress included dosing initiation for ARV-6723 and submission of ARV-393 data for ASH, but the revenue collapse from the Pfizer deal transition and ongoing cash burn are the dominant financial facts.

Key Financial Metrics

Revenue
$500.0K
-98.8% YoY

Key Facts

  • Q3 2026 revenue was $0.5M, down from $41.9M in Q3 2025, as Pfizer collaboration revenue did not recur after the Rigel out-license.
  • Cash, cash equivalents, restricted cash, and marketable securities were $558.9M as of September 30, 2026, down from $685.4M at December 31, 2025.
  • Cash used in operations for the nine months ended September 30, 2026 was $123.0M (net of $35.0M received under the Rigel License Agreement).
  • Initiated dosing in the Phase 1/2 trial of ARV-6723 (HPK1 degrader) in patients with advanced solid tumors.
  • Submitted initial Phase 1 monotherapy dose escalation data for ARV-393 (BCL6 degrader) for presentation at ASH in December 2026.
  • ARV-102 IND remains on hold in the U.S.; company plans to initiate Phase 1b trial in PSP in the EU and UK in 2027.
  • Cash runway guidance reaffirmed into the second half of 2028.

Financial Impact

Revenue collapsed from $41.9M to $0.5M YoY; operating loss widened to $59.1M from $43.8M; cash burn of $126.5M in nine months.

revenuenet incomecash position

Risk Factors

  • Revenue is now minimal ($0.5M/quarter from Rigel royalties) with no near-term catalyst for a material increase.
  • ARV-102 IND remains on hold in the U.S., limiting the PSP trial to EU/UK and delaying U.S. enrollment.
  • All pipeline programs are in Phase 1; clinical data readouts carry binary risk.
  • Cash burn of ~$14M/month implies ~40 months of runway, but any trial delays or additional programs could accelerate spending.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
57% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-069101
Exhibit: exhibit992-arvinascorpor.htm0001628280-26-069101
Document: arvn-20261103.htm0001628280-26-069101
Document: 0001628280-26-069101-index-headers.html0001628280-26-069101
Document: 0001628280-26-069101-index.html0001628280-26-069101
Document: 0001628280-26-069101.txt0001628280-26-069101
8-K Data (Synthetic)0001628280-26-069101

Track record

21 reports on ARVN

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
  2. Nov 3, 202613d ago 8-K Bearish 5/10 Viewing No price data
  3. Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
  4. Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
  5. Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
  6. Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
  7. May 12, 202626w ago 8-K Mixed 6/10 No price data
  8. May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
  9. May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
  10. May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 25m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026